Logo

Lilly Signs a License Agreement with Asahi Kasei Pharma for AK1780 to Treat Chronic Pain

Share this
Lilly Signs a License Agreement with Asahi Kasei Pharma for AK1780 to Treat Chronic Pain

Lilly Signs a License Agreement with Asahi Kasei Pharma for AK1780 to Treat Chronic Pain

Shots:

  • Asahi Kasei to receive an $20M up front- ~$210M as development & regulatory milestones and will be eligible for ~$180M milestones along with royalties on sales of the therapy.
  • Lilly to acquire the exclusive rights for AK1780 while Asahi Kasei will retain the right to promote AK1780 in Japan and China (including Hong Kong and Macau)
  • AK1780 is an orally bioavailable P2X7 receptor antagonist that has completed its P-I single and multiple ascending dose and clinical pharmacology studies for chronic pain conditions

 ­ Ref: PRNewswire | Image: Lilly 

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions